pancreatic cancer
Immunovia Receives Pennsylvania, Maryland Clinical Lab Permits
The company can now provide its ImmRay PanCan-d test to detect stage I and stage II pancreatic cancer in at-risk patients to clinicians in 48 states.
Immunovia Cleared to Offer Pancreatic Cancer Test in Rhode Island
The test is designed to detect nine serum biomarkers of pancreatic ductal adenocarcinoma, including the protein CA19-9.
Pancreatic Cancer Application Provides First Toehold for Biological Dynamics in Clinical Testing
Premium
The company is validating early promising data for an exosomal-protein based signature to identify asymptomatic individuals with early pancreatic cancer.
Immunovia, JW BioScience Ink Licensing Agreement for Early Pancreatic Cancer Detection Biomarkers
Immunovia said that it has secured intellectual property rights to the biomarkers, which are part of the diagnostic signature for its Immray PanCan-d blood test.
Immunovia Receives Massachusetts Approval to Begin Testing of Patients for Pancreatic Cancer
The firm said its laboratory developed test, which recognizes biomarker signatures in the blood, can detect pancreatic cancer early when surgical resection is possible.